Register
Login

Trending Topic

11 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, an estimated 2.48 million new cases of lung cancer were reported in 2022.4,5 Although lung cancer rates in the […]

Corey Cutler, ASH 2019: Evolving Treatment for Patients with GvHD

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 18th 2019

At the 61st ASH Annual Meeting & Exposition, Corey Cutler, Dana Farber Cancer Institute, discusses his presentation: The Evolving Treatment Landscape for Patients with GvHD: More Options, More Decisions, Better Outcomes!

Questions

1. What are the major challenges in the treatment of patients with graft-versus-host disease (GvHD)? (0:05)

2. How have recent advances in understanding of the biology of GvHD impacted on patient management? (0:45)

3. What do you consider the most important emerging therapies for GvHD? (1:22)

4. What do healthcare professionals need to know in terms of monitoring and appropriate management of treatment-related adverse events? (1:54)

5. What other key messages of this symposium would you like to highlight? (2:33)

 

Corey Cutler has no conflicts of interest to declare in relation to this video.

Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.

 

 

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup